Proceedings · Session S-668 · filed November 18, 2026

Translational ScienceSession paper

Cancer Vaccine Beats Survival Endpoint, But Patent Clock Looms

SELLAS's GPS vaccine cut death risk 41% in AML, but core patents expire from 2026 and one Chinese CDMO makes its second drug.

By Amara Osei2 min read398 words

Summary

  • GPS extended median survival to 24.0 months vs 14.7 months on best available treatment — a 41% lower death risk
  • Trial p-value was 0.035; confidence intervals and survival curves remain unpublished, and the trial was open-label
  • Original U.S. patents on GPS peptides expire from 2026; Memorial Sloan Kettering owns most underlying science
  • SELLAS launched a $150 million share offering hours after the stock rose 156% in one session
  • FDA decision expected in 2027; SLS009 is manufactured entirely by Shanghai-based GenFleet under BIOSECURE-era risk
Can a Cancer Vaccine Win the Trial but Lose the Patent Race?
FigureCan a Cancer Vaccine Win the Trial but Lose the Patent Race? — garten-gg / pixabay

SELLAS Life Sciences reported that its leukemia vaccine galinpepimut-S (GPS) extended median survival to 24.0 months in a pivotal Phase 3 trial, against 14.7 months for best available treatment — a 41% lower risk of death. The result came from the REGAL trial in patients with acute myeloid leukemia (AML) in second remission. Within hours of the readout, the Nasdaq-listed company launched a $150 million share offering, after its stock rose 156% in a single session.

The mechanism is specific. GPS uses modified peptides that train the immune system to attack WT1, a protein many leukemias overproduce. Earlier WT1 vaccines failed against bulky solid tumors, so SELLAS restricted its target population to patients with only residual disease after chemotherapy. No approved maintenance therapy exists in this setting, which sharpens the commercial question.

What the trial data does — and does not — show?

The disclosed numbers carry caveats that R&D evaluators should weigh. Key statistics remain unpublished, including the confidence interval and the survival curves. The reported p-value of 0.035 leaves little statistical margin, and the trial was open-label, a design that can bias survival assessments when investigators know treatment assignment.

Measured results and projections must be kept apart. The 24.0-month median overall survival is a measured endpoint. Everything downstream — FDA action, full-data confirmation, commercial scale — remains a projection.

Why does the patent position matter?

The untold story sits in intellectual property and supply chain. Several of the original U.S. patents covering GPS peptides expire from 2026 onward. Memorial Sloan Kettering owns most of the underlying science, meaning SELLAS does not control the foundational IP. As a result, FDA exclusivity, not patents, would form the real moat after any approval.

The supply chain carries its own concentration risk. SELLAS's second drug, SLS009, comes from Shanghai-based GenFleet, which also manufactures every dose. The BIOSECURE Act is already law, so that dependence carries growing geopolitical weight — even though the trials run in the United States and Europe.

What happens next?

For investors and portfolio planners, the trial has shifted the debate rather than settled it. Three questions now dominate:

  • How the FDA responds in 2027
  • Whether full published data confirm the survival benefit
  • How much dilution the $150 million offering adds for existing shareholders

SELLAS has crossed its clinical hurdle. The regulatory, commercial, and geopolitical hurdles still lie ahead.

via tradingview.com (Source)

Filed under

  • cancer-vaccines
  • galinpepimut-s
  • acute-myeloid-leukemia
  • phase-3-clinical-trials
  • intellectual-property
Share this article:

More from Amara Osei

Amara Osei

Show full bio

News editor covering money, funding and market shifts around research and development at Hypothesis Wire.

253 articles

References

  1. Cretostimogene Cuts Bladder Cancer Recurrence Risk 68% in Phase 3
  2. Agenus Brings BOT+BAL Survival Data and agenT-797 Findings to SITC 2026
  3. Neladalkib Wins Accelerated Approval: 49% ORR After Alectinib
  4. Agenus Brings BOT/BAL Survival Data to SITC 2026
  5. Six-Gene PHFScore Predicts AML Survival, CRG Team Reports

« Previous article